Cargando…
Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
Immune checkpoint inhibitors represent a major therapeutic advance in non-small-cell lung cancer with several approved anti-programmed death-1 and anti-programmed death-L1 immunotherapies. A majority of patients however, will not respond to immune checkpoint inhibitors and display primary resistance...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992482/ https://www.ncbi.nlm.nih.gov/pubmed/35582440 http://dx.doi.org/10.20517/cdr.2020.14 |